Beigene
Clinical trials sponsored by Beigene, explained in plain language.
-
First human test of experimental cancer drug halted
Disease control TerminatedThis early-stage study aimed to find a safe dose of a new drug called BGB-24714 for people with advanced solid tumors that have spread or cannot be removed by surgery. Researchers tested the drug by itself and combined with chemotherapy or radiation to see how well patients toler…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
First human test of new Cancer-Fighting antibody begins
Disease control TerminatedThis is an early-stage study to test the safety and find the right dose of a new drug called BGB-B3227 for people with advanced or metastatic solid tumors. The drug will be tested both by itself and in combination with another cancer drug, tislelizumab. The main goals are to see …
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
First human test of experimental cancer combo halted early
Disease control TerminatedThis early-stage study tested a new oral drug called BGB-30813, both alone and combined with the immunotherapy drug tislelizumab, in people with advanced cancers that had spread. The main goals were to find safe doses and check for early signs that the treatments might help shrin…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Halted trial tests new hope for lymphoma patients Who've run out of options
Disease control TerminatedThis study aimed to test whether a new immunotherapy drug called tislelizumab works better than standard chemotherapy for people with Hodgkin lymphoma that has returned or stopped responding to previous treatments. The trial was designed to enroll many patients but was stopped ea…
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC